Maman BiomedicalTM



Alleviating Pain, Nurturing Families™

COMPANY

Website: https://mamanbiomedical.ca/

Year Established: 2024

Patents/Trademarks: In-progress

Stage: MVP - Validating

Industry: Life Sciences – Fem Tech

E-mail Address: info@mamanbiomedical.ca

TEAM

Founders and Management Team:

Founder & CEO - Dr. Latchmi Raghunanan, PhD Materials Science. 13 years expertise translating soft matter chemistry from bench to scale, 5 granted patents, 15 peer-reviewed publications, 4 years leading R&D, & IP at a medical device startup.

Co-founder & CBO - Roopchand Raghunanan, PMP, PgMP. 20 years executive-level leadership expertise in organizational process development.

Co-founder & COO - Lauren Franzoni. Life Science, Commerce and VC expertise.

Board of Advisors:

Reproductive Endocrinologist, Reproductive Biologist, Regulatory Expert, Biomaterials Translational Scientist, Startup Expert.

FINANCIAL INFO

Revenue: Pre-revenue Monthly Burn: \$36,000 Funding to Date: \$104,500

Capital Seeking: \$250,000 F&F, Sept 2024

USE OF FUNDS

Strategy: Leverage \$250,000 into \$430,000 through non-dilutive grants.

53% Product Development (Salaries, lab, equipment, consumables, trials). 12% Business Development (Conferences). 8% Operations (Office rent, non-R&D salary, insurance, IT, travel).

27% Legal (IP, accounting, tax).

COMPANY OVERVIEW

Problem: Infertility affects every 1 in 5 couples in North America, and in vitro fertilization (IVF) is a common solution. However, the current IVF standard of care requires upwards of 20 injections over 8-10 days, making the process invasive and uncomfortable.

Value Proposition Statement: We eliminate the pain and inconvenience of repeated injections with our innovative drug delivery solutions, ensuring consistent dosage and minimal impact on lifestyle.

Technology: Maman Biomedical is pioneering slow-release drug delivery systems to revolutionize fertility treatment:

- Maman Gel[™], our single-injection product that maintains effective hormone levels for the entire treatment cycle; and
- Maman Patch™, our needle-free alternative that provides consistent hormone delivery without injections.

Current State of Development: MVP testing and validation stages.

MARKET

Target Market: North American fertility market, valued at \$20B in 2021. Market Opportunity: Maman Patch™: \$1B; Maman Gel™: \$3.5B

BUSINESS MODEL AND TRACTION

Revenue Model: Sales to Pharmacies. *Maman Patch™:* premium-priced; Maman Gel™: value-priced.

Go to Market Strategy: Partnerships with fertility clinics and doctors established during product development.

Distribution Model/Channel Partners: Licencing agreements with major pharmaceutical manufacturers who will use their established distribution channels to Fertility Clinics and Pharmaceutical suppliers.

Current Traction: Ongoing discussions with 3 Clinics and 5 Reproductive Endocrinologists; early agreements for 2 pilot studies; lab space secured; patent and trademark searches in progress; 50k of current Family & Friends fundraising round already committed.

MILESTONE PLAN

Milestones:

- Next 3 months: In Lab R&D commences, Provisional Patent filed.
- At 6 Months: Pilot animal study completed: Pre-seed funding round in-progress, product feedback and refinement commenced.
- At 12 Months: Additions to Provisional Patent filed, Trademarks secured, early pre-clinical validation commenced.

Activities and Resources: Research & Product Development. Resources: 1 Materials Scientist (CEO expertise); 1 Mitacs postdoc (Biology); 2 interns (Chemistry, Clinical); lab space, consumables & freeze-dryer; pilot trial & Key Opinion Leader fee; operations and legal services.

Challenges: We're aggressively raising a back-to-back \$250k Friends and Family round and a \$1.5M Pre-Seed round; we're on the lookout for a lead investor, deep pockets, and follow-on investors.

PARTNERS















BioNeXt



